Table 2: MIPS Benchmark Results ,,,,,,,,,,,,,,
,,,,,,,,,,,,,,
Measure_Name,Measure_ID,Submission_Method,Measure_Type,Benchmark,Decile 3,Decile 4,Decile 5,Decile 6,Decile 7,Decile 8,Decile 9,Decile 10,Topped Out,
Diabetes: Hemoglobin A1c Poor Control,1,Claims,Outcome,Y, 35.00 - 25.72, 25.71 - 20.32, 20.31 - 16.23, 16.22 - 13.05, 13.04 - 10.01, 10.00 -  7.42,  7.41 -  4.01,<=  4.00,No,
Diabetes: Hemoglobin A1c Poor Control,1,EHR,Outcome,Y, 54.67 - 35.91, 35.90 - 25.63, 25.62 - 19.34, 19.33 - 14.15, 14.14 -  9.10,  9.09 -  3.34,  3.33 -  0.01,  0.00,No,
Diabetes: Hemoglobin A1c Poor Control,1,Registry/QCDR,Outcome,Y, 83.10 - 68.19, 68.18 - 53.14, 53.13 - 40.66, 40.65 - 30.20, 30.19 - 22.74, 22.73 - 16.82, 16.81 - 10.33,<= 10.32,No,
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,100,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,100,Registry/QCDR,Process,Y, 83.96 - 96.96, 96.97 - 99.99,--,--,--,--,--,100.00,Yes,
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,Registry/QCDR,Process,Y, 42.12 - 54.99, 55.00 - 71.72, 71.73 - 82.13, 82.14 - 99.46, 99.47 - 99.99,--,--,100.00,No,
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,EHR,Process,N,--,--,--,--,--,--,--,--,--,
Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients,104,Registry/QCDR,Process,Y, 77.31 - 80.64, 80.65 - 91.19, 91.20 - 96.66, 96.67 - 98.82, 98.83 - 99.99,--,--,100.00,Yes,
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,EHR,Process,Y, 53.85 - 64.74, 64.75 - 70.90, 70.91 - 86.68, 86.69 - 89.31, 89.32 - 92.90, 92.91 - 96.54, 96.55 - 98.67,>= 98.68,No,
Osteoarthritis (OA): Function and Pain Assessment,109,Claims,Process,Y, 80.92 - 94.14, 94.15 - 98.67, 98.68 - 99.99,--,--,--,--,100.00,Yes,
Osteoarthritis (OA): Function and Pain Assessment,109,Registry/QCDR,Process,Y,  5.16 - 14.84, 14.85 - 37.78, 37.79 - 65.33, 65.34 - 88.04, 88.05 - 97.81, 97.82 - 99.99,--,100.00,No,
Preventive Care and Screening: Influenza Immunization,110,Claims,Process,Y, 22.64 - 31.75, 31.76 - 43.13, 43.14 - 54.68, 54.69 - 66.38, 66.39 - 77.47, 77.48 - 92.03, 92.04 - 99.99,100.00,No,
Preventive Care and Screening: Influenza Immunization,110,EHR,Process,Y, 11.22 - 18.57, 18.58 - 24.99, 25.00 - 31.84, 31.85 - 38.92, 38.93 - 47.86, 47.87 - 59.99, 60.00 - 79.01,>= 79.02,No,
Preventive Care and Screening: Influenza Immunization,110,Registry/QCDR,Process,Y, 11.57 - 21.39, 21.40 - 31.39, 31.40 - 41.31, 41.32 - 51.13, 51.14 - 62.04, 62.05 - 74.27, 74.28 - 91.83,>= 91.84,No,
Pneumonia Vaccination Status for Older Adults,111,Claims,Process,Y, 39.78 - 51.32, 51.33 - 61.67, 61.68 - 70.47, 70.48 - 77.77, 77.78 - 84.49, 84.50 - 91.99, 92.00 - 99.06,>= 99.07,No,
Pneumonia Vaccination Status for Older Adults,111,EHR,Process,Y, 14.13 - 23.25, 23.26 - 33.02, 33.03 - 43.58, 43.59 - 53.96, 53.97 - 63.60, 63.61 - 74.54, 74.55 - 85.52,>= 85.53,No,
Pneumonia Vaccination Status for Older Adults,111,Registry/QCDR,Process,Y, 12.24 - 24.02, 24.03 - 36.34, 36.35 - 48.51, 48.52 - 58.95, 58.96 - 68.05, 68.06 - 77.77, 77.78 - 90.19,>= 90.20,No,
Breast Cancer Screening,112,Claims,Process,Y, 38.46 - 48.01, 48.02 - 55.67, 55.68 - 62.78, 62.79 - 69.41, 69.42 - 77.18, 77.19 - 87.87, 87.88 - 98.52,>= 98.53,No,
Breast Cancer Screening,112,EHR,Process,Y, 12.41 - 22.21, 22.22 - 32.30, 32.31 - 40.86, 40.87 - 47.91, 47.92 - 55.25, 55.26 - 63.06, 63.07 - 73.22,>= 73.23,No,
Breast Cancer Screening,112,Registry/QCDR,Process,Y, 14.49 - 24.52, 24.53 - 35.70, 35.71 - 46.01, 46.02 - 55.06, 55.07 - 63.67, 63.68 - 74.06, 74.07 - 87.92,>= 87.93,No,
Colorectal Cancer Screening,113,Claims,Process,Y, 29.50 - 42.36, 42.37 - 53.84, 53.85 - 64.40, 64.41 - 75.40, 75.41 - 84.67, 84.68 - 93.13, 93.14 - 99.99,100.00,No,
Colorectal Cancer Screening,113,EHR,Process,Y,  7.35 - 15.97, 15.98 - 24.66, 24.67 - 33.45, 33.46 - 44.39, 44.40 - 56.19, 56.20 - 67.91, 67.92 - 82.28,>= 82.29,No,
Colorectal Cancer Screening,113,Registry/QCDR,Process,Y, 10.08 - 20.68, 20.69 - 32.73, 32.74 - 45.20, 45.21 - 55.95, 55.96 - 66.31, 66.32 - 77.01, 77.02 - 88.14,>= 88.15,No,
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis,116,Registry/QCDR,Process,Y, 23.19 - 31.47, 31.48 - 63.74, 63.75 - 99.99,--,--,--,--,100.00,Yes,
Diabetes: Eye Exam,117,Claims,Process,Y, 86.36 - 97.77, 97.78 - 99.99,--,--,--,--,--,100.00,Yes,
Diabetes: Eye Exam,117,EHR,Process,Y, 50.57 - 80.68, 80.69 - 90.05, 90.06 - 94.11, 94.12 - 96.66, 96.67 - 98.57, 98.58 - 99.99,--,100.00,No,
Diabetes: Eye Exam,117,Registry/QCDR,Process,Y, 69.39 - 89.68, 89.69 - 95.95, 95.96 - 98.72, 98.73 - 99.99,--,--,--,100.00,Yes,
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%),118,Registry/QCDR,Process,Y, 71.03 - 74.18, 74.19 - 76.51, 76.52 - 78.94, 78.95 - 81.10, 81.11 - 83.99, 84.00 - 87.79, 87.80 - 95.99,>= 96.00,No,
Diabetes: Medical Attention for Nephropathy,119,Claims,Process,Y, 61.76 - 73.84, 73.85 - 82.49, 82.50 - 88.88, 88.89 - 93.64, 93.65 - 97.21, 97.22 - 99.99,--,100.00,No,
Diabetes: Medical Attention for Nephropathy,119,EHR,Process,Y, 66.67 - 72.91, 72.92 - 78.12, 78.13 - 82.26, 82.27 - 86.12, 86.13 - 89.95, 89.96 - 93.32, 93.33 - 96.63,>= 96.64,No,
Diabetes: Medical Attention for Nephropathy,119,Registry/QCDR,Process,Y, 66.24 - 73.41, 73.42 - 79.16, 79.17 - 83.01, 83.02 - 86.95, 86.96 - 90.47, 90.48 - 94.51, 94.52 - 99.70,>= 99.71,No,
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Claims,Process,Y, 99.01 - 99.99,--,--,--,--,--,--,100.00,Yes,
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,EHR,Process,Y, 73.33 - 82.41, 82.42 - 87.39, 87.40 - 90.90, 90.91 - 94.16, 94.17 - 96.57, 96.58 - 98.25, 98.26 - 99.57,>= 99.58,No,
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Registry/QCDR,Process,Y, 95.07 - 98.10, 98.11 - 99.35, 99.36 - 99.99,--,--,--,--,100.00,Yes,
Adult Kidney Disease: Laboratory Testing (Lipid Profile),121,Registry/QCDR,Process,Y, 20.00 - 34.26, 34.27 - 45.70, 45.71 - 58.96, 58.97 - 69.48, 69.49 - 78.60, 78.61 - 90.15, 90.16 - 99.99,100.00,No,
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,Registry/QCDR,Process,Y, 10.34 - 18.46, 18.47 - 28.94, 28.95 - 41.66, 41.67 - 60.23, 60.24 - 75.20, 75.21 - 89.89, 89.90 - 99.99,100.00,No,
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,Registry/QCDR,Process,Y,  4.26 - 11.10, 11.11 - 22.80, 22.81 - 39.99, 40.00 - 61.69, 61.70 - 79.56, 79.57 - 93.74, 93.75 - 99.99,100.00,No,
Documentation of Current Medications in the Medical Record,130,Claims,Process,Y, 96.11 - 98.73, 98.74 - 99.64, 99.65 - 99.99,--,--,--,--,100.00,Yes,
Documentation of Current Medications in the Medical Record,130,EHR,Process,Y, 76.59 - 87.88, 87.89 - 92.73, 92.74 - 95.35, 95.36 - 97.08, 97.09 - 98.27, 98.28 - 99.12, 99.13 - 99.75,>= 99.76,Yes,
Documentation of Current Medications in the Medical Record,130,Registry/QCDR,Process,Y, 61.27 - 82.11, 82.12 - 91.71, 91.72 - 96.86, 96.87 - 99.30, 99.31 - 99.99,--,--,100.00,Yes,
Pain Assessment and Follow-Up,131,Claims,Process,Y, 75.66 - 95.78, 95.79 - 99.33, 99.34 - 99.99,--,--,--,--,100.00,Yes,
Pain Assessment and Follow-Up,131,Registry/QCDR,Process,Y,  8.91 - 26.13, 26.14 - 50.11, 50.12 - 72.57, 72.58 - 91.42, 91.43 - 99.02, 99.03 - 99.99,--,100.00,No,
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,Claims,Process,Y, 11.54 - 30.67, 30.68 - 62.08, 62.09 - 94.03, 94.04 - 99.45, 99.46 - 99.99,--,--,100.00,No,
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,EHR,Process,Y,  1.22 -  2.93,  2.94 -  5.93,  5.94 - 11.09, 11.10 - 17.87, 17.88 - 30.29, 30.30 - 51.32, 51.33 - 72.63,>= 72.64,No,
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan,134,Registry/QCDR,Process,Y,  2.01 -  5.26,  5.27 - 14.88, 14.89 - 32.90, 32.91 - 50.42, 50.43 - 64.99, 65.00 - 85.25, 85.26 - 99.99,100.00,No,
Melanoma: Continuity of Care - Recall System,137,Registry/QCDR,Structure,Y, 53.73 - 75.75, 75.76 - 88.45, 88.46 - 98.07, 98.08 - 99.99,--,--,--,100.00,No,
Melanoma: Coordination of Care,138,Registry/QCDR,Process,Y, 35.19 - 66.66, 66.67 - 88.88, 88.89 - 96.54, 96.55 - 99.99,--,--,--,100.00,Yes,
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Registry/QCDR,Process,Y, 31.01 - 55.12, 55.13 - 77.24, 77.25 - 91.17, 91.18 - 98.18, 98.19 - 99.99,--,--,100.00,No,
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement,140,Claims,Process,Y, 97.50 - 99.99,--,--,--,--,--,--,100.00,Yes,
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement,140,Registry/QCDR,Process,Y, 32.26 - 48.38, 48.39 - 65.54, 65.55 - 78.94, 78.95 - 89.99, 90.00 - 97.43, 97.44 - 99.99,--,100.00,No,
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Registry/QCDR,Process,Y, 78.95 - 93.68, 93.69 - 98.03, 98.04 - 99.75, 99.76 - 99.99,--,--,--,100.00,Yes,
Oncology: Medical and Radiation - Pain Intensity Quantified,143,EHR,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Oncology: Medical and Radiation - Pain Intensity Quantified,143,Registry/QCDR,Process,Y, 35.53 - 76.18, 76.19 - 82.13, 82.14 - 90.20, 90.21 - 96.76, 96.77 - 99.99,--,--,100.00,No,
Oncology: Medical and Radiation - Plan of Care for Pain,144,Registry/QCDR,Process,Y, 33.64 - 48.19, 48.20 - 66.91, 66.92 - 78.41, 78.42 - 85.83, 85.84 - 99.11, 99.12 - 99.99,--,100.00,No,
Radiology: Exposure Time Reported for Procedures Using Fluoroscopy,145,Claims,Process,Y, 69.33 - 83.10, 83.11 - 89.99, 90.00 - 93.80, 93.81 - 96.13, 96.14 - 97.82, 97.83 - 99.77, 99.78 - 99.99,100.00,No,
Radiology: Exposure Time Reported for Procedures Using Fluoroscopy,145,Registry/QCDR,Process,Y, 67.86 - 77.99, 78.00 - 84.61, 84.62 - 89.77, 89.78 - 93.41, 93.42 - 96.66, 96.67 - 99.59, 99.60 - 99.99,100.00,No,
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Mammography Screening",146,Claims,Process,Y,  0.31 -  0.01,--,--,--,--,--,--,  0.00,Yes,
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Mammography Screening",146,Registry/QCDR,Process,Y,  4.77 -  2.75,  2.74 -  1.25,  1.24 -  0.52,  0.51 -  0.15,  0.14 -  0.01,--,--,  0.00,Yes,
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Claims,Structure,Y, 50.00 - 65.37, 65.38 - 77.77, 77.78 - 86.95, 86.96 - 93.74, 93.75 - 96.96, 96.97 - 99.99,--,100.00,No,
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Registry/QCDR,Structure,Y, 59.52 - 71.10, 71.11 - 83.09, 83.10 - 91.66, 91.67 - 96.54, 96.55 - 99.33, 99.34 - 99.99,--,100.00,No,
Falls: Risk Assessment,154,Claims,Process,Y, 88.89 - 98.75, 98.76 - 99.99,--,--,--,--,--,100.00,Yes,
Falls: Risk Assessment,154,Registry/QCDR,Process,Y,  7.81 - 19.99, 20.00 - 38.12, 38.13 - 57.62, 57.63 - 84.16, 84.17 - 99.82, 99.83 - 99.99,--,100.00,No,
Falls: Plan of Care,155,Claims,Process,Y, 34.78 - 55.55, 55.56 - 86.26, 86.27 - 99.11, 99.12 - 99.99,--,--,--,100.00,Yes,
Falls: Plan of Care,155,Registry/QCDR,Process,Y, 20.00 - 41.43, 41.44 - 62.11, 62.12 - 75.44, 75.45 - 85.99, 86.00 - 93.32, 93.33 - 98.07, 98.08 - 99.99,100.00,No,
Oncology: Radiation Dose Limits to Normal Tissues,156,Registry/QCDR,Process,Y, 93.10 - 96.76, 96.77 - 97.72, 97.73 - 99.99,--,--,--,--,100.00,Yes,
Oncology: Radiation Dose Limits to Normal Tissues,156,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Diabetes: Foot Exam,163,Claims,Process,Y, 37.84 - 54.28, 54.29 - 71.87, 71.88 - 86.51, 86.52 - 96.66, 96.67 - 99.99,--,--,100.00,No,
Diabetes: Foot Exam,163,EHR,Process,Y,  5.31 - 10.90, 10.91 - 19.99, 20.00 - 29.26, 29.27 - 38.77, 38.78 - 50.09, 50.10 - 62.60, 62.61 - 76.16,>= 76.17,No,
Diabetes: Foot Exam,163,Registry/QCDR,Process,Y,  6.14 - 14.70, 14.71 - 25.57, 25.58 - 39.80, 39.81 - 55.87, 55.88 - 72.21, 72.22 - 86.43, 86.44 - 98.03,>= 98.04,No,
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,164,Registry/QCDR,Outcome,Y, 12.16 - 10.65, 10.64 -  9.29,  9.28 -  7.56,  7.55 -  6.30,  6.29 -  4.97,  4.96 -  3.59,  3.58 -  1.83,<=  1.82,No,
Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate,165,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,  0.00,Yes,
Coronary Artery Bypass Graft (CABG): Stroke,166,Registry/QCDR,Outcome,Y,  2.41 -  1.96,  1.95 -  1.39,  1.38 -  0.88,  0.87 -  0.01,--,--,--,  0.00,Yes,
Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure,167,Registry/QCDR,Outcome,Y,  3.70 -  3.04,  3.03 -  2.48,  2.47 -  1.91,  1.90 -  1.38,  1.37 -  0.30,  0.29 -  0.01,--,  0.00,Yes,
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration,168,Registry/QCDR,Outcome,Y,  3.60 -  2.79,  2.78 -  2.09,  2.08 -  1.63,  1.62 -  1.25,  1.24 -  0.90,  0.89 -  0.01,--,  0.00,Yes,
Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula,172,Claims,Process,Y, 88.54 - 95.44, 95.45 - 99.99,--,--,--,--,--,100.00,Yes,
Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula,172,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Preventive Care and Screening: Unhealthy Alcohol Use - Screening,173,Registry/QCDR,Process,Y, 48.93 - 62.39, 62.40 - 71.86, 71.87 - 80.71, 80.72 - 88.21, 88.22 - 94.43, 94.44 - 98.48, 98.49 - 99.99,100.00,No,
Rheumatoid Arthritis (RA): Functional Status Assessment,178,Registry/QCDR,Process,Y, 27.99 - 45.95, 45.96 - 64.17, 64.18 - 74.46, 74.47 - 81.36, 81.37 - 87.82, 87.83 - 92.34, 92.35 - 99.71,>= 99.72,No,
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy,18,EHR,Process,Y, 31.69 - 41.32, 41.33 - 49.99, 50.00 - 56.97, 56.98 - 64.17, 64.18 - 70.58, 70.59 - 76.97, 76.98 - 85.15,>= 85.16,No,
Elder Maltreatment Screen and Follow-Up Plan,181,Claims,Process,Y,  7.69 - 91.72, 91.73 - 99.27, 99.28 - 99.99,--,--,--,--,100.00,Yes,
Elder Maltreatment Screen and Follow-Up Plan,181,Registry/QCDR,Process,Y, 28.80 - 42.30, 42.31 - 51.95, 51.96 - 67.46, 67.47 - 85.94, 85.95 - 97.24, 97.25 - 99.65, 99.66 - 99.99,100.00,No,
Functional Outcome Assessment,182,Claims,Process,Y, 98.46 - 99.90, 99.91 - 99.99,--,--,--,--,--,100.00,Yes,
Functional Outcome Assessment,182,Registry/QCDR,Process,Y, 94.35 - 97.47, 97.48 - 99.20, 99.21 - 99.99,--,--,--,--,100.00,Yes,
Colonoscopy Interval for Patients with a History of Adenomatous Polyps ? Avoidance of Inappropriate Use ? National Quality Strategy Domain: Communication and Care Coordination,185,Claims,Process,Y, 98.82 - 99.99,--,--,--,--,--,--,100.00,Yes,
Colonoscopy Interval for Patients with a History of Adenomatous Polyps ? Avoidance of Inappropriate Use ? National Quality Strategy Domain: Communication and Care Coordination,185,Registry/QCDR,Process,Y, 81.08 - 88.67, 88.68 - 93.23, 93.24 - 96.19, 96.20 - 98.27, 98.28 - 99.99,--,--,100.00,Yes,
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,Registry/QCDR,Outcome,Y, 14.55 - 34.99, 35.00 - 43.74, 43.75 - 52.37, 52.38 - 66.66, 66.67 - 76.24, 76.25 - 96.66, 96.67 - 99.99,100.00,No,
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,EHR,Process,Y, 20.00 - 29.78, 29.79 - 38.35, 38.36 - 45.70, 45.71 - 52.53, 52.54 - 60.79, 60.80 - 68.80, 68.81 - 79.30,>= 79.31,No,
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Registry/QCDR,Process,Y, 36.21 - 59.99, 60.00 - 78.56, 78.57 - 89.80, 89.81 - 96.22, 96.23 - 99.99,--,--,100.00,No,
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,EHR,Outcome,Y, 86.61 - 91.42, 91.43 - 94.43, 94.44 - 96.07, 96.08 - 97.35, 97.36 - 98.30, 98.31 - 99.24, 99.25 - 99.99,100.00,No,
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,Registry/QCDR,Outcome,Y, 42.89 - 59.56, 59.57 - 83.17, 83.18 - 91.52, 91.53 - 94.84, 94.85 - 96.79, 96.80 - 99.25, 99.26 - 99.99,100.00,No,
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,EHR,Outcome,Y,  0.92 -  0.43,  0.42 -  0.01,--,--,--,--,--,  0.00,Yes,
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,Registry/QCDR,Outcome,Y,  1.60 -  0.75,  0.74 -  0.24,  0.23 -  0.01,--,--,--,--,  0.00,Yes,
Perioperative Temperature Management,193,Claims,Outcome,Y, 92.50 - 95.82, 95.83 - 97.64, 97.65 - 98.71, 98.72 - 99.45, 99.46 - 99.99,--,--,100.00,Yes,
Perioperative Temperature Management,193,Registry/QCDR,Outcome,Y, 98.18 - 99.99,--,--,--,--,--,--,100.00,Yes,
Oncology: Cancer Stage Documented,194,Registry/QCDR,Process,Y,  5.00 -  9.81,  9.82 - 23.88, 23.89 - 62.49, 62.50 - 83.01, 83.02 - 94.86, 94.87 - 99.82, 99.83 - 99.99,100.00,No,
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Claims,Process,Y, 78.57 - 87.49, 87.50 - 92.49, 92.50 - 95.78, 95.79 - 97.66, 97.67 - 99.62, 99.63 - 99.99,--,100.00,Yes,
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Registry/QCDR,Process,Y, 82.98 - 90.90, 90.91 - 94.49, 94.50 - 96.76, 96.77 - 98.40, 98.41 - 99.99,--,--,100.00,Yes,
Diabetes: Low Density Lipoprotein (LDL-C) Control (<100 mg/dL),2,Registry/QCDR,Outcome,Y,  0.83 -  1.06,  1.07 -  1.35,  1.36 -  1.82,  1.83 -  2.51,  2.52 -  3.53,  3.54 -  6.45,  6.46 - 25.57,>= 25.58,No,
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic,204,Claims,Process,Y, 84.09 - 87.17, 87.18 - 89.46, 89.47 - 91.29, 91.30 - 93.05, 93.06 - 94.99, 95.00 - 96.76, 96.77 - 99.99,100.00,No,
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic,204,EHR,Process,Y, 55.21 - 63.76, 63.77 - 69.99, 70.00 - 74.99, 75.00 - 78.78, 78.79 - 81.99, 82.00 - 85.03, 85.04 - 88.69,>= 88.70,No,
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic,204,Registry/QCDR,Process,Y, 68.03 - 75.75, 75.76 - 80.76, 80.77 - 84.61, 84.62 - 87.92, 87.93 - 90.94, 90.95 - 94.73, 94.74 - 99.99,100.00,No,
"HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis",205,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Registry/QCDR,Process,Y, 91.17 - 99.10, 99.11 - 99.99,--,--,--,--,--,100.00,Yes,
Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments,217,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments,218,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
"Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments",219,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures),22,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures),22,Registry/QCDR,Process,Y, 45.69 - 77.37, 77.38 - 97.77, 97.78 - 99.99,--,--,--,--,100.00,Yes,
Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments,220,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments,221,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
"Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments",222,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
"Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments",223,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Melanoma: Overutilization of Imaging Studies in Melanoma,224,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Radiology: Reminder System for Screening Mammograms,225,Claims,Structure,Y, 89.85 - 98.64, 98.65 - 99.99,--,--,--,--,--,100.00,No,
Radiology: Reminder System for Screening Mammograms,225,Registry/QCDR,Structure,Y, 99.89 - 99.99,--,--,--,--,--,--,100.00,Yes,
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Claims,Process,Y, 95.60 - 97.85, 97.86 - 99.25, 99.26 - 99.99,--,--,--,--,100.00,Yes,
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,EHR,Process,Y, 72.59 - 81.59, 81.60 - 86.68, 86.69 - 90.15, 90.16 - 92.64, 92.65 - 94.67, 94.68 - 96.58, 96.59 - 98.51,>= 98.52,No,
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Registry/QCDR,Process,Y, 76.67 - 85.53, 85.54 - 89.87, 89.88 - 92.85, 92.86 - 95.14, 95.15 - 97.21, 97.22 - 99.10, 99.11 - 99.99,100.00,No,
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Registry/QCDR,Process,Y, 89.74 - 96.66, 96.67 - 99.99,--,--,--,--,--,100.00,Yes,
Controlling High Blood Pressure,236,Claims,Process,Y, 57.69 - 63.44, 63.45 - 68.28, 68.29 - 72.78, 72.79 - 77.06, 77.07 - 81.47, 81.48 - 86.75, 86.76 - 93.42,>= 93.43,No,
Controlling High Blood Pressure,236,EHR,Process,Y, 50.00 - 55.39, 55.40 - 59.72, 59.73 - 63.59, 63.60 - 67.38, 67.39 - 71.00, 71.01 - 75.33, 75.34 - 80.89,>= 80.90,No,
Controlling High Blood Pressure,236,Registry/QCDR,Process,Y, 51.00 - 58.20, 58.21 - 63.56, 63.57 - 68.27, 68.28 - 72.40, 72.41 - 76.69, 76.70 - 82.75, 82.76 - 91.06,>= 91.07,No,
"Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older",24,Claims,Process,Y, 75.00 - 91.29, 91.30 - 96.42, 96.43 - 99.99,--,--,--,--,100.00,Yes,
"Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older",24,Registry/QCDR,Process,Y,  8.00 - 10.33, 10.34 - 12.49, 12.50 - 17.06, 17.07 - 21.87, 21.88 - 49.99, 50.00 - 82.49, 82.50 - 99.99,100.00,No,
Childhood Immunization Status,240,EHR,Process,Y,  4.76 -  6.51,  6.52 -  9.08,  9.09 - 13.00, 13.01 - 18.17, 18.18 - 23.80, 23.81 - 29.32, 29.33 - 41.66,>= 41.67,No,
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Barrett's Esophagus,249,Claims,Structure,Y,--,--,--,--,--,--,--,100.00,Yes,
Barrett's Esophagus,249,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes,
Radical Prostatectomy Pathology Reporting,250,Claims,Structure,Y,--,--,--,--,--,--,--,100.00,Yes,
Radical Prostatectomy Pathology Reporting,250,Registry/QCDR,Structure,N,--,--,--,--,--,--,--,--,--,
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients,251,Claims,Structure,Y,--,--,--,--,--,--,--,100.00,Yes,
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients,251,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes,
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Statin Therapy at Discharge after Lower Extremity Bypass (LEB),257,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7),258,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2),259,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
"Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)",260,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Image Confirmation of Successful Excision of Image-Localized Breast Lesion,262,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Image Confirmation of Successful Excision of Image-Localized Breast Lesion,262,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Preoperative Diagnosis of Breast Cancer,263,Registry/QCDR,Process,Y, 97.95 - 98.91, 98.92 - 99.99,--,--,--,--,--,100.00,Yes,
Preoperative Diagnosis of Breast Cancer,263,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Sentinel Lymph Node Biopsy for Invasive Breast Cancer,264,Registry/QCDR,Process,Y, 97.01 - 97.99, 98.00 - 98.89, 98.90 - 99.99,--,--,--,--,100.00,Yes,
Biopsy Follow-Up,265,Registry/QCDR,Process,Y, 24.44 - 53.53, 53.54 - 78.78, 78.79 - 94.99, 95.00 - 99.99,--,--,--,100.00,Yes,
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Claims,Outcome,N,--,--,--,--,--,--,--,--,--,
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy,270,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment,271,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy,274,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy,275,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Dementia: Cognitive Assessment,281,EHR,Process,Y,  5.66 - 17.56, 17.57 - 30.76, 30.77 - 56.25, 56.26 - 78.05, 78.06 - 88.13, 88.14 - 95.55, 95.56 - 99.99,100.00,No,
Dementia: Cognitive Assessment,281,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery,303,Registry/QCDR,Outcome,Y,  5.76 -  9.37,  9.38 - 23.80, 23.81 - 29.87, 29.88 - 43.60, 43.61 - 56.69, 56.70 - 94.33, 94.34 - 99.99,100.00,No,
Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery,304,Registry/QCDR,Outcome,Y,  5.32 -  7.68,  7.69 - 21.69, 21.70 - 26.67, 26.68 - 39.60, 39.61 - 46.60, 46.61 - 83.07, 83.08 - 99.99,100.00,No,
Cervical Cancer Screening,309,EHR,Process,Y,  8.89 - 15.08, 15.09 - 21.79, 21.80 - 28.83, 28.84 - 36.66, 36.67 - 44.99, 45.00 - 54.77, 54.78 - 68.99,>= 69.00,No,
Cervical Cancer Screening,309,Registry/QCDR,Process,Y, 28.95 - 35.91, 35.92 - 43.02, 43.03 - 45.56, 45.57 - 49.25, 49.26 - 51.40, 51.41 - 53.78, 53.79 - 59.23,>= 59.24,No,
Chlamydia Screening for Women,310,EHR,Process,Y,  8.33 - 12.86, 12.87 - 18.17, 18.18 - 24.99, 25.00 - 33.32, 33.33 - 39.99, 40.00 - 49.99, 50.00 - 61.53,>= 61.54,No,
Chlamydia Screening for Women,310,Registry/QCDR,Process,Y,  6.06 -  7.18,  7.19 -  9.08,  9.09 - 10.23, 10.24 - 11.53, 11.54 - 13.78, 13.79 - 18.17, 18.18 - 20.86,>= 20.87,No,
Use of Appropriate Medications for Asthma,311,EHR,Process,Y, 16.67 - 41.02, 41.03 - 58.05, 58.06 - 69.05, 69.06 - 75.48, 75.49 - 81.81, 81.82 - 87.49, 87.50 - 92.97,>= 92.98,No,
Use of Appropriate Medications for Asthma,311,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Use of Imaging Studies for Low Back Pain,312,EHR,Process,Y, 83.12 - 90.47, 90.48 - 96.14, 96.15 - 99.99,--,--,--,--,100.00,Yes,
Use of Imaging Studies for Low Back Pain,312,Registry/QCDR,Process,Y, 55.00 - 91.99, 92.00 - 99.99,--,--,--,--,--,100.00,Yes,
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Claims,Process,Y, 42.13 - 50.44, 50.45 - 59.06, 59.07 - 68.11, 68.12 - 78.63, 78.64 - 92.67, 92.68 - 99.53, 99.54 - 99.99,100.00,No,
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,EHR,Process,Y, 17.90 - 22.55, 22.56 - 25.80, 25.81 - 28.83, 28.84 - 31.69, 31.70 - 34.67, 34.68 - 38.96, 38.97 - 46.26,>= 46.27,No,
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Registry/QCDR,Process,Y, 24.74 - 35.47, 35.48 - 47.87, 47.88 - 62.14, 62.15 - 71.64, 71.65 - 79.36, 79.37 - 88.85, 88.86 - 98.87,>= 98.88,No,
Falls: Screening for Future Fall Risk,318,EHR,Process,Y,  6.33 - 17.92, 17.93 - 31.98, 31.99 - 47.86, 47.87 - 63.81, 63.82 - 81.04, 81.05 - 90.20, 90.21 - 98.49,>= 98.50,No,
Falls: Screening for Future Fall Risk,318,Registry/QCDR,Process,Y,  0.11 -  0.11,  0.12 -  0.14,  0.15 -  0.20,  0.21 -  0.28,  0.29 -  0.50,  0.51 - 55.23, 55.24 - 92.20,>= 92.21,No,
Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy,32,Claims,Process,Y, 51.16 - 63.63, 63.64 - 87.99, 88.00 - 96.42, 96.43 - 99.99,--,--,--,100.00,Yes,
Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy,32,Registry/QCDR,Process,Y, 27.17 - 46.29, 46.30 - 67.85, 67.86 - 80.85, 80.86 - 90.90, 90.91 - 96.42, 96.43 - 99.99,--,100.00,No,
Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Claims,Process,Y, 90.00 - 95.44, 95.45 - 99.99,--,--,--,--,--,100.00,Yes,
Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Registry/QCDR,Process,Y, 81.82 - 90.69, 90.70 - 95.44, 95.45 - 98.11, 98.12 - 99.99,--,--,--,100.00,Yes,
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,322,Registry/QCDR,Efficiency,Y,  2.67 -  0.54,  0.53 -  0.01,--,--,--,--,--,  0.00,Yes,
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),323,Registry/QCDR,Efficiency,Y,  1.00 -  0.01,--,--,--,--,--,--,  0.00,Yes,
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,Registry/QCDR,Efficiency,Y,  3.38 -  0.79,  0.78 -  0.01,--,--,--,--,--,  0.00,Yes,
Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions,325,Registry/QCDR,Process,Y, 91.30 - 98.50, 98.51 - 99.99,--,--,--,--,--,100.00,Yes,
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Claims,Process,Y, 94.09 - 96.85, 96.86 - 99.37, 99.38 - 99.99,--,--,--,--,100.00,Yes,
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Registry/QCDR,Process,Y, 20.00 - 39.18, 39.19 - 52.33, 52.34 - 69.56, 69.57 - 76.18, 76.19 - 82.49, 82.50 - 94.33, 94.34 - 99.99,100.00,No,
Pediatric Kidney Disease: Adequacy of Volume Management,327,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis,329,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge,33,Registry/QCDR,Process,Y, 29.55 - 43.18, 43.19 - 55.77, 55.78 - 73.75, 73.76 - 87.79, 87.80 - 95.22, 95.23 - 99.99,--,100.00,No,
Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days,330,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Appropriate Use),331,Registry/QCDR,Process,Y, 89.07 - 82.41, 82.40 - 71.44, 71.43 - 46.46, 46.45 - 16.91, 16.90 -  0.60,  0.59 -  0.01,--,  0.00,No,
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin Prescribed for Patients with Acute Bacterial Sinusitis,332,Registry/QCDR,Process,Y, 44.39 - 47.99, 48.00 - 51.88, 51.89 - 57.57, 57.58 - 64.99, 65.00 - 72.72, 72.73 - 95.99, 96.00 - 99.99,100.00,No,
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse),333,Registry/QCDR,Outcome,Y,  2.13 -  0.66,  0.65 -  0.01,--,--,--,--,--,  0.00,Yes,
Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse),334,Registry/QCDR,Outcome,Y,  2.25 -  1.73,  1.72 -  1.12,  1.11 -  0.01,--,--,--,--,  0.00,Yes,
Maternity Care: Elective Delivery or Early Induction Without Medical Indication at >= 37 and < 39 Weeks,335,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Maternity Care: Post-Partum Follow-Up and Care Coordination,336,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Tuberculosis Prevention for Psoriasis and Psoriatic Arthritis Patients on a Biological Immune Response Modifier,337,Registry/QCDR,Process,Y,  6.82 - 16.12, 16.13 - 24.13, 24.14 - 47.59, 47.60 - 90.90, 90.91 - 99.99,--,--,100.00,No,
Pain Brought Under Control within 48 Hours,342,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Screening Colonoscopy Adenoma Detection Rate,343,Registry/QCDR,Outcome,Y, 29.63 - 38.09, 38.10 - 41.85, 41.86 - 45.70, 45.71 - 48.69, 48.70 - 56.51, 56.52 - 63.40, 63.41 - 80.32,>= 80.33,No,
"Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)",344,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS),345,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA),346,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital,347,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate,348,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Patient-Centered Surgical Risk Assessment and Communication,358,Registry/QCDR,Process,Y,  8.47 - 27.02, 27.03 - 78.25, 78.26 - 95.23, 95.24 - 99.99,--,--,--,100.00,Yes,
Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computerized Tomography (CT) Imaging Description,359,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes,362,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes,
"Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Imaging Studies Through a Secure, Authorized, Media-Free, Shared Archive",363,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes,
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Hemoglobin A1c Test for Pediatric Patients,365,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Bipolar Disorder and Major Depression: Appraisal for Alcohol or Chemical Substance Use,367,EHR,Process,N,--,--,--,--,--,--,--,--,--,
HIV/AIDS: Medical Visit,368,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Pregnant Women that had HBsAg Testing,369,EHR,Process,N,--,--,--,--,--,--,--,--,--,
Pregnant Women that had HBsAg Testing,369,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Depression Remission at Twelve Months,370,EHR,Outcome,N,--,--,--,--,--,--,--,--,--,
Maternal Depression Screening,372,EHR,Process,N,--,--,--,--,--,--,--,--,--,
Hypertension: Improvement in Blood Pressure,373,EHR,Outcome,Y,  6.82 -  9.31,  9.32 - 11.70, 11.71 - 14.40, 14.41 - 17.39, 17.40 - 21.44, 21.45 - 27.61, 27.62 - 39.04,>= 39.05,No,
Hypertension: Improvement in Blood Pressure,373,Registry/QCDR,Outcome,Y,  2.39 -  2.93,  2.94 -  3.46,  3.47 -  3.92,  3.93 -  4.71,  4.72 -  5.53,  5.54 -  6.74,  6.75 -  9.99,>= 10.00,No,
Closing the Referral Loop: Receipt of Specialist Report,374,EHR,Process,Y,  2.70 -  6.24,  6.25 - 11.46, 11.47 - 18.15, 18.16 - 25.57, 25.58 - 36.95, 36.96 - 51.17, 51.18 - 71.87,>= 71.88,No,
Functional Status Assessment for Knee Replacement,375,EHR,Process,Y,  5.36 -  9.51,  9.52 -  9.99, 10.00 - 43.95, 43.96 - 47.82, 47.83 - 54.54, 54.55 - 66.04, 66.05 - 85.18,>= 85.19,No,
Functional Status Assessment for Hip Replacement,376,EHR,Process,N,--,--,--,--,--,--,--,--,--,
Functional Status Assessment for Complex Chronic Conditions,377,EHR,Process,N,--,--,--,--,--,--,--,--,--,
Children Who Have Dental Decay or Cavities,378,EHR,Outcome,Y,  0.36 -  0.01,--,--,--,--,--,--,  0.00,Yes,
Children Who Have Dental Decay or Cavities,378,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,EHR,Process,Y,  0.79 -  0.96,  0.97 -  1.62,  1.63 -  2.03,  2.04 -  4.26,  4.27 -  6.59,  6.60 -  7.88,  7.89 - 14.28,>= 14.29,No,
ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range,380,EHR,Outcome,N,--,--,--,--,--,--,--,--,--,
HIV/AIDS: RNA Control for Patients with HIV,381,EHR,Outcome,Y, 19.47 - 27.84, 27.85 - 33.42, 33.43 - 42.85, 42.86 - 76.26, 76.27 - 84.99, 85.00 - 90.31, 90.32 - 92.49,>= 92.50,No,
HIV/AIDS: RNA Control for Patients with HIV,381,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,EHR,Process,Y,  4.84 - 10.64, 10.65 - 16.29, 16.30 - 28.56, 28.57 - 92.97, 92.98 - 98.50, 98.51 - 99.33, 99.34 - 99.99,100.00,No,
Adherence to Antipsychotic Medications for Individuals with Schizophrenia,383,Registry/QCDR,Outcome,Y, 34.78 - 60.50, 60.51 - 72.36, 72.37 - 80.54, 80.55 - 91.99, 92.00 - 99.99,--,--,100.00,No,
Adult Primary Rhegmatogenous Retinal Detachment Repair Success Rate,384,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Adult Primary Rhegmatogenous Retinal Detachment Surgery Success Rate,385,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences,386,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users,387,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vsitrectomy),388,Registry/QCDR,Outcome,Y,  0.26 -  0.01,--,--,--,--,--,--,  0.00,Yes,
Cataract Surgery: Difference Between Planned and Final Refraction,389,Registry/QCDR,Outcome,Y, 66.67 - 88.45, 88.46 - 94.11, 94.12 - 98.09, 98.10 - 99.99,--,--,--,100.00,No,
Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older,39,Claims,Process,Y, 30.77 - 39.54, 39.55 - 46.74, 46.75 - 53.96, 53.97 - 61.89, 61.90 - 70.86, 70.87 - 82.53, 82.54 - 95.87,>= 95.88,No,
Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older,39,Registry/QCDR,Process,Y, 13.39 - 16.66, 16.67 - 20.39, 20.40 - 25.31, 25.32 - 33.99, 34.00 - 47.94, 47.95 - 64.65, 64.66 - 82.53,>= 82.54,No,
Discussion and Shared Decision Making Surrounding Treatment Options,390,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
"HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision",393,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Claims,Process,Y, 91.30 - 97.49, 97.50 - 99.99,--,--,--,--,--,100.00,Yes,
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Registry/QCDR,Process,Y, 93.75 - 99.65, 99.66 - 99.99,--,--,--,--,--,100.00,Yes,
Lung Cancer Reporting (Resection Specimens),396,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Lung Cancer Reporting (Resection Specimens),396,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Melanoma Reporting,397,Claims,Process,Y, 68.33 - 78.42, 78.43 - 95.11, 95.12 - 99.99,--,--,--,--,100.00,Yes,
Melanoma Reporting,397,Registry/QCDR,Process,Y, 47.22 - 92.67, 92.68 - 99.99,--,--,--,--,--,100.00,Yes,
Optimal Asthma Control,398,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
"Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older",40,Claims,Process,Y, 15.00 - 27.99, 28.00 - 36.14, 36.15 - 49.99, 50.00 - 75.30, 75.31 - 92.85, 92.86 - 99.99,--,100.00,No,
"Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older",40,Registry/QCDR,Process,Y,  5.00 -  6.95,  6.96 -  8.69,  8.70 - 16.13, 16.14 - 32.78, 32.79 - 47.40, 47.41 - 65.56, 65.57 - 88.88,>= 88.89,No,
Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk,400,Registry/QCDR,Process,Y,  1.19 -  1.33,  1.34 -  1.53,  1.54 -  1.71,  1.72 -  2.09,  2.10 -  2.92,  2.93 -  8.32,  8.33 - 20.01,>= 20.02,No,
Screening for Hepatocellular Carcinoma (HCC) in patients with Hepatitis C Cirrhosis,401,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Tobacco Use and Help with Quitting Among Adolescents,402,Registry/QCDR,Process,Y, 74.10 - 81.15, 81.16 - 87.49, 87.50 - 90.37, 90.38 - 92.72, 92.73 - 95.15, 95.16 - 97.50, 97.51 - 99.99,100.00,No,
Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older,41,Claims,Process,Y, 33.33 - 40.45, 40.46 - 46.66, 46.67 - 58.32, 58.33 - 74.50, 74.51 - 96.45, 96.46 - 99.99,--,100.00,No,
Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older,41,Registry/QCDR,Process,Y, 33.33 - 40.43, 40.44 - 46.28, 46.29 - 52.77, 52.78 - 59.25, 59.26 - 66.66, 66.67 - 75.58, 75.59 - 99.99,100.00,No,
Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery,43,Registry/QCDR,Process,Y, 98.17 - 98.69, 98.70 - 99.99,--,--,--,--,--,100.00,Yes,
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery,44,Claims,Process,Y, 96.84 - 99.99,--,--,--,--,--,--,100.00,Yes,
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery,44,Registry/QCDR,Process,Y, 91.14 - 94.99, 95.00 - 97.32, 97.33 - 98.87, 98.88 - 99.99,--,--,--,100.00,Yes,
Advance Care Plan,47,Claims,Process,Y, 13.68 - 34.57, 34.58 - 62.86, 62.87 - 86.91, 86.92 - 97.10, 97.11 - 99.59, 99.60 - 99.99,--,100.00,No,
Advance Care Plan,47,Registry/QCDR,Process,Y, 16.52 - 38.11, 38.12 - 59.14, 59.15 - 74.99, 75.00 - 88.71, 88.72 - 96.29, 96.30 - 99.17, 99.18 - 99.99,100.00,No,
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Claims,Process,Y,  6.25 - 20.42, 20.43 - 64.72, 64.73 - 96.76, 96.77 - 99.99,--,--,--,100.00,Yes,
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Registry/QCDR,Process,Y, 16.31 - 29.03, 29.04 - 42.90, 42.91 - 57.07, 57.08 - 76.52, 76.53 - 89.12, 89.13 - 96.91, 96.92 - 99.99,100.00,No,
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,EHR,Process,Y, 62.16 - 66.66, 66.67 - 71.42, 71.43 - 74.90, 74.91 - 77.60, 77.61 - 82.60, 82.61 - 85.70, 85.71 - 90.90,>= 90.91,No,
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,Registry/QCDR,Process,Y, 75.86 - 79.48, 79.49 - 82.13, 82.14 - 84.99, 85.00 - 87.49, 87.50 - 89.99, 90.00 - 93.53, 93.54 - 96.54,>= 96.55,No,
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Claims,Process,Y, 92.86 - 97.02, 97.03 - 99.99,--,--,--,--,--,100.00,Yes,
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Registry/QCDR,Process,Y, 73.48 - 86.08, 86.09 - 94.33, 94.34 - 97.66, 97.67 - 99.99,--,--,--,100.00,Yes,
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Claims,Process,Y, 21.61 - 59.99, 60.00 - 85.49, 85.50 - 96.61, 96.62 - 99.99,--,--,--,100.00,Yes,
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Registry/QCDR,Process,Y, 50.53 - 58.59, 58.60 - 69.43, 69.44 - 77.97, 77.98 - 86.43, 86.44 - 93.17, 93.18 - 97.65, 97.66 - 99.99,100.00,No,
Chronic Obstructive Pulmonary Disease (COPD): Inhaled Bronchodilator Therapy,52,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Chronic Obstructive Pulmonary Disease (COPD): Inhaled Bronchodilator Therapy,52,Registry/QCDR,Process,Y, 95.24 - 99.99,--,--,--,--,--,--,100.00,Yes,
Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain,54,Claims,Process,Y, 95.45 - 96.87, 96.88 - 98.03, 98.04 - 99.99,--,--,--,--,100.00,Yes,
Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain,54,Registry/QCDR,Process,Y, 95.45 - 98.26, 98.27 - 99.55, 99.56 - 99.99,--,--,--,--,100.00,Yes,
Coronary Artery Disease (CAD): Antiplatelet Therapy,6,Registry/QCDR,Process,Y, 76.92 - 81.75, 81.76 - 84.99, 85.00 - 87.53, 87.54 - 90.22, 90.23 - 92.54, 92.55 - 95.64, 95.65 - 99.99,100.00,No,
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,EHR,Process,Y, 70.45 - 79.99, 80.00 - 87.99, 88.00 - 93.05, 93.06 - 95.64, 95.65 - 97.29, 97.30 - 98.96, 98.97 - 99.99,100.00,No,
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,Registry/QCDR,Process,Y, 67.74 - 80.76, 80.77 - 91.07, 91.08 - 94.74, 94.75 - 99.99,--,--,--,100.00,No,
Appropriate Testing for Children with Pharyngitis,66,EHR,Process,Y, 38.12 - 52.32, 52.33 - 67.64, 67.65 - 74.56, 74.57 - 80.94, 80.95 - 85.70, 85.71 - 89.15, 89.16 - 94.20,>= 94.21,No,
Appropriate Testing for Children with Pharyngitis,66,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow,67,Registry/QCDR,Process,Y, 95.00 - 96.87, 96.88 - 98.69, 98.70 - 99.99,--,--,--,--,100.00,Yes,
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy,68,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Hematology: Multiple Myeloma: Treatment with Bisphosphonates,69,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry,70,Registry/QCDR,Process,Y, 86.52 - 95.23, 95.24 - 99.50, 99.51 - 99.99,--,--,--,--,100.00,Yes,
Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer,71,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer,71,Registry/QCDR,Process,Y, 80.49 - 90.78, 90.79 - 96.48, 96.49 - 98.07, 98.08 - 99.99,--,--,--,100.00,Yes,
Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients,72,Claims,Process,N,--,--,--,--,--,--,--,--,--,
Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients,72,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Prevention of Central Venous Catheter (CVC)-Related Bloodstream Infections,76,Claims,Process,Y, 85.71 - 94.28, 94.29 - 97.17, 97.18 - 99.42, 99.43 - 99.99,--,--,--,100.00,Yes,
Prevention of Central Venous Catheter (CVC)-Related Bloodstream Infections,76,Registry/QCDR,Process,Y, 89.66 - 95.99, 96.00 - 99.99,--,--,--,--,--,100.00,Yes,
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,EHR,Process,Y, 58.62 - 64.70, 64.71 - 71.94, 71.95 - 78.25, 78.26 - 85.50, 85.51 - 89.99, 90.00 - 91.66, 91.67 - 95.99,>= 96.00,No,
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,Registry/QCDR,Process,Y, 75.68 - 81.07, 81.08 - 85.57, 85.58 - 88.43, 88.44 - 91.16, 91.17 - 94.28, 94.29 - 96.36, 96.37 - 99.99,100.00,No,
Adult Kidney Disease: Hemodialysis Adequacy: Solute,81,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute,82,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Acute Otitis Externa (AOE): Topical Therapy,91,Claims,Process,Y, 60.87 - 85.70, 85.71 - 96.96, 96.97 - 99.99,--,--,--,--,100.00,Yes,
Acute Otitis Externa (AOE): Topical Therapy,91,Registry/QCDR,Process,Y, 60.47 - 69.56, 69.57 - 78.25, 78.26 - 83.01, 83.02 - 87.97, 87.98 - 93.32, 93.33 - 99.99,--,100.00,No,
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Claims,Process,Y, 94.29 - 95.64, 95.65 - 97.29, 97.30 - 99.99,--,--,--,--,100.00,Yes,
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Registry/QCDR,Process,Y, 73.91 - 84.74, 84.75 - 90.90, 90.91 - 95.82, 95.83 - 99.99,--,--,--,100.00,Yes,
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,99,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,99,Registry/QCDR,Process,Y, 97.62 - 99.99,--,--,--,--,--,--,100.00,Yes,
Asthma Assessment and Classification,AAAAI 11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Lung Function/Spirometry Evaluation,AAAAI 12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Asthma Control: Minimal Important Difference Improvement,AAAAI 17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Penicillin Allergy: Appropriate Removal or Confirmation,AAAAI 18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Asthma: Assessment of Asthma Control - Ambulatory Care Setting,AAAAI 2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Allergen Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment,AAAAI 5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Documentation of Clinical Response to Allergen Immunotherapy within One Year,AAAAI 6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year,AAAAI 8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Assessment of Asthma Symptoms Prior to Administration of Allergen Immunotherapy Injection(s),AAAAI 9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Anesthesia Safety in the Peri-Operative Period,ABG 1,Registry/QCDR,Outcome,Y, 99.44 - 99.54, 99.55 - 99.83, 99.84 - 99.99,--,--,--,--,100.00,Yes,
Anesthesia: Patient Experience Survey,ABG 12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Corneal Abrasion,ABG 14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
PACU Intubation Rate,ABG 4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Composite Procedural Safety for All Vascular Access Procedures,ABG 5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Immediate Adult Post-Operative Pain Management,ABG 7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Hypertension (HTN): Blood Pressure (BP) Management,ACCPin 1,Registry/QCDR,Process,Y, 80.04 - 84.15, 84.16 - 86.65, 86.66 - 88.55, 88.56 - 89.84, 89.85 - 91.05, 91.06 - 92.34, 92.35 - 93.89,>= 93.90,No,
Coronary Artery Disease (CAD): Blood Pressure Control,ACCPin 2,Registry/QCDR,Outcome,Y, 81.51 - 85.87, 85.88 - 88.51, 88.52 - 90.49, 90.50 - 91.71, 91.72 - 92.90, 92.91 - 94.15, 94.16 - 95.53,>= 95.54,No,
Gout: Serum Urate Target,ACR 7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRad 16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Report Turnaround Time: CT,ACRad 18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Report Turnaround Time: PET,ACRad 19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
CT Colonography Clinically Significant Extracolonic Findings,ACRad 2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Lung Cancer Screening Abnormal Interpretation Rate,ACRad 23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Screening Mammography Cancer Detection Rate (CDR),ACRad 3,Registry/QCDR,Outcome,Y,  3.54 -  4.32,  4.33 -  4.80,  4.81 -  5.15,  5.16 -  5.47,  5.48 -  5.71,  5.72 -  6.68,  6.69 -  8.10,>=  8.11,No,
Screening Mammography Abnormal Interpretation Rate (Recall Rate),ACRad 5,Registry/QCDR,Outcome,Y, 13.98 - 11.03, 11.02 -  9.94,  9.93 -  9.24,  9.23 -  8.21,  8.20 -  7.22,  7.21 -  6.39,  6.38 -  5.27,<=  5.26,No,
Screening Mammography Positive Predictive Value 2 (PPV2 - BiopsyRecommended),ACRad 6,Registry/QCDR,Outcome,Y, 13.53 - 17.90, 17.91 - 20.33, 20.34 - 21.54, 21.55 - 24.99, 25.00 - 28.25, 28.26 - 39.46, 39.47 - 42.58,>= 42.59,No,
Screening Mammography Node Negativity Rate,ACRad 7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Screening Mammography Minimal Cancer Rate,ACRad 8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,AQI 18,Registry/QCDR,Outcome,Y, 91.06 - 94.96, 94.97 - 98.83, 98.84 - 99.63, 99.64 - 99.99,--,--,--,100.00,Yes,
Surgeon assessment for hereditary cause of breast cancer,ASBS 1,Registry/QCDR,Process,Y, 98.70 - 99.41, 99.42 - 99.99,--,--,--,--,--,100.00,Yes,
Unplanned 30 day re-operation after mastectomy,ASBS 7,Registry/QCDR,Outcome,Y, 95.45 - 97.05, 97.06 - 98.83, 98.84 - 99.99,--,--,--,--,100.00,Yes,
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,ASNC 1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),ASNC 2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
"Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",ASNC 3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Utilization of standardized nomenclature and reporting for nuclear cardiology imaging studies,ASNC 4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Transfusion goal of hematocrit less than 30,ASPIRE 13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Avoiding intraoperative hypotension,ASPIRE 16,Registry/QCDR,Process,Y, 91.67 - 92.72, 92.73 - 94.61, 94.62 - 99.54, 99.55 - 99.72, 99.73 - 99.85, 99.86 - 99.88, 99.89 - 99.99,100.00,Yes,
Avoiding myocardial Injury,ASPIRE 18,Registry/QCDR,Outcome,Y, 98.82 - 99.01, 99.02 - 99.26, 99.27 - 99.36, 99.37 - 99.41, 99.42 - 99.46, 99.47 - 99.67, 99.68 - 99.75,>= 99.76,No,
Train of Four Monitor Documented After Last Dose of Non-depolarizing Neuromuscular Blocker,ASPIRE 2,Registry/QCDR,Process,Y, 78.96 - 80.94, 80.95 - 82.72, 82.73 - 83.47, 83.48 - 84.42, 84.43 - 86.07, 86.08 - 88.08, 88.09 - 90.33,>= 90.34,No,
Avoiding medication overdose,ASPIRE 22,Registry/QCDR,Outcome,Y, 99.29 - 99.30, 99.31 - 99.37, 99.38 - 99.50, 99.51 - 99.63, 99.64 - 99.68, 99.69 - 99.75, 99.76 - 99.87,>= 99.88,No,
Administration of Neostigmine before Extubation for Cases with Nondepolarizing Neuromuscular Blockade,ASPIRE 3,Registry/QCDR,Process,Y, 89.03 - 90.25, 90.26 - 93.55, 93.56 - 96.79, 96.80 - 97.96, 97.97 - 98.41, 98.42 - 98.89, 98.90 - 99.30,>= 99.31,Yes,
Administration of insulin or glucose recheck for patients with hyperglycemia,ASPIRE 4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Avoiding excessively high tidal volumes during positive pressure ventilation,ASPIRE 6,Registry/QCDR,Process,Y, 89.66 - 91.38, 91.39 - 92.67, 92.68 - 94.06, 94.07 - 95.28, 95.29 - 95.46, 95.47 - 95.97, 95.98 - 96.54,>= 96.55,No,
Adequate Off-loading of Diabetic Foot Ulcers at each visit,CDR 1,Registry/QCDR,Process,Y, 40.13 - 58.05, 58.06 - 72.34, 72.35 - 83.92, 83.93 - 91.29, 91.30 - 95.29, 95.30 - 97.41, 97.42 - 98.87,>= 98.88,No,
Vascular Assessment of patients with chronic leg ulcers,CDR 10,Registry/QCDR,Process,Y, 28.14 - 36.46, 36.47 - 43.95, 43.96 - 57.95, 57.96 - 68.13, 68.14 - 73.73, 73.74 - 77.31, 77.32 - 79.51,>= 79.52,No,
Diabetic Foot Ulcer (DFU) Healing or Closure,CDR 2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Adequate Compression at each visit for Patients with Venous Leg Ulcers (VLU),CDR 5,Registry/QCDR,Process,Y, 75.20 - 90.31, 90.32 - 93.58, 93.59 - 94.63, 94.64 - 95.82, 95.83 - 97.23, 97.24 - 99.09, 99.10 - 99.99,100.00,No,
Venous Leg Ulcer outcome measure: Healing or Closure,CDR 6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Plan of Care for Venous Leg Ulcer Patients not Achieving 30% Closure at 4 Weeks,CDR 7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Appropriate use of hyperbaric oxygen therapy for patients with diabetic foot ulcers,CDR 8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Appropriate use of Cellular or Tissue Based Products (CTP) for patients aged 18 years or older with a diabetic foot ulcer (DFU) or venous leg ulcer (VLU),CDR 9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Three Day All Cause Return ED Visit Rate - All Patients,ECPR 11,Registry/QCDR,Outcome,Y,  6.46 -  6.05,  6.04 -  5.72,  5.71 -  5.40,  5.39 -  5.08,  5.07 -  4.76,  4.75 -  4.35,  4.34 -  3.94,<=  3.93,No,
Door to Diagnostic Evaluation by a Provider - Adult Emergency Department (ED) Patients,ECPR 2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Lower Acuity ED Patients,ECPR 5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Higher Acuity ED Patients,ECPR 6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Appropriate management of anticoagulation in the peri-procedural period rate - EGD,GIQIC 10,Registry/QCDR,Process,Y, 68.37 - 89.99, 90.00 - 97.91, 97.92 - 99.99,--,--,--,--,100.00,Yes,
Appropriate indication for colonoscopy,GIQIC 12,Registry/QCDR,Process,Y, 82.27 - 86.05, 86.06 - 89.06, 89.07 - 91.34, 91.35 - 93.27, 93.28 - 94.80, 94.81 - 96.59, 96.60 - 98.44,>= 98.45,No,
Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients,GIQIC 15,Registry/QCDR,Process,Y, 68.18 - 74.32, 74.33 - 77.87, 77.88 - 80.70, 80.71 - 85.23, 85.24 - 89.17, 89.18 - 91.34, 91.35 - 94.38,>= 94.39,No,
Mean Length of Stay for Inpatients - CHF,HCPR 4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Mean Length of Stay for Inpatients - COPD,HCPR 5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Corneal Graft: 20/40 or Better Visual Acuity within 90 Days following Corneal Graft Surgery,IRIS 1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Exudative Age-Related Macular Degeneration: Loss of Visual Acuity,IRIS 10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity,IRIS 11,Registry/QCDR,Outcome,Y, 72.97 - 79.58, 79.59 - 85.70, 85.71 - 95.58, 95.59 - 97.43, 97.44 - 99.99,--,--,100.00,No,
Diabetic Macular Edema: Loss of Visual Acuity,IRIS 13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Acute Anterior Uveitis: Post-treatment visual acuity,IRIS 16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells,IRIS 17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Chronic Anterior Uveitis: Post-treatment visual acuity,IRIS 18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells,IRIS 19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Open-Angle Glaucoma: Intraocular Pressure Reduction,IRIS 2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Open-Angle Glaucoma: Visual Field Progression,IRIS 3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Open-Angle Glaucoma: Intraocular Pressure Reduction Following Laser Trabeculoplasty,IRIS 4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Acquired Involutional Ptosis: Improvement of Marginal Reflex Distance within 90 Days Following Surgery for Acquired Involutional Ptosis,IRIS 5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Acquired Involutional Entropion: Normalization of Eyelid Position within 90 Days Following Surgery for Acquired Involutional Entropion,IRIS 6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Amblyopia: Improvement of Corrected Interocular Visual Acuity Difference to 2 or fewer Lines,IRIS 7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Surgical Esotropia: Patients with Postoperative Alignment of 15 PD or less,IRIS 8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Diabetic Retinopathy: Dilated Eye Exam,IRIS 9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Procedures with statin and antiplatelet agents prescribed at discharge,M2S 1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Imaging-based maximum aortic diameter assessed at one-year following Endovascular AAA Repair procedures,M2S 11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Ipsilateral stroke-free survival at one-year following isolated CEA for asymptomatic procedures,M2S 8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Imaging-based maximum aortic diameter assessed at one-year following Thoracic and Complex EVAR procedures,M2S 9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
"Risk standardized rate of patients who experienced an unplanned readmission (likely related to the initial operation) to any hospital within 30 days following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy operation, performed as a primary (not revisional) procedure.",MBSAQIP 2,Registry/QCDR,Outcome,Y,  4.84 -  3.73,  3.72 -  3.24,  3.23 -  2.96,  2.95 -  1.86,  1.85 -  1.16,  1.15 -  0.01,--,  0.00,Yes,
"Risk standardized rate of patients who experienced a reoperation (likely related to the initial operation) within 30 days following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy operation, performed as a primary (not revisional) procedure.",MBSAQIP 3,Registry/QCDR,Outcome,Y,  2.38 -  1.73,  1.72 -  0.62,  0.61 -  0.01,--,--,--,--,  0.00,Yes,
"Risk standardized rate of patients who experienced an anastomotic/staple line leak within 30 days following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy operation, performed as a primary (not revisional) procedure.",MBSAQIP 4,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,  0.00,Yes,
"Risk standardized rate of patients who experienced a postoperative surgical site infection (SSI) (superficial incisional, deep incisional, or organ/space SSI) within 30 days following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy operation, performed as a primary (not revisional) procedure.",MBSAQIP 6,Registry/QCDR,Outcome,Y,  1.61 -  0.64,  0.63 -  0.01,--,--,--,--,--,  0.00,Yes,
"Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion within 30 days following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy operation, performed as a primary (not revisional) procedure.",MBSAQIP 7,Registry/QCDR,Outcome,Y,  2.56 -  2.27,  2.26 -  1.53,  1.52 -  0.79,  0.78 -  0.01,--,--,--,  0.00,Yes,
"Risk standardized rate of patients who experienced extended length of stay (> 7 days) following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy operation, performed as a primary (not revisional) procedure.",MBSAQIP 8,Registry/QCDR,Outcome,Y,  1.37 -  0.54,  0.53 -  0.01,--,--,--,--,--,  0.00,Yes,
Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy,MUSIC 1,Registry/QCDR,Process,Y, 94.12 - 97.82, 97.83 - 98.10, 98.11 - 99.28, 99.29 - 99.99,--,--,--,100.00,Yes,
Unplanned Hospital Admission within 30 Days of TRUS Biopsy:,MUSIC 2,Registry/QCDR,Outcome,Y,  1.28 -  0.01,--,--,--,--,--,--,  0.00,Yes,
Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients:,MUSIC 3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Prostate Cancer: Proportion of patients with low-risk prostate cancer receiving active surveillance,MUSIC 4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Prostate Cancer: Percentage of prostate cancer cases with a length of stay > 2 days,MUSIC 5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy:,MUSIC 6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Prostate Biopsy: Proportion of patients undergoing a repeat prostate biopsy within 12 months of their initial biopsy in the registry as a result of a finding of atypical small acinar proliferation (ASAP) as per the NCCN guidelines,MUSIC 9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
CG--?CAHPS Adult Visit Composite Tracking,OBERD 12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
30 day Readmission for Acute Myocardial Infarction,PInc 1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
30 day Readmission for Heart Failure,PInc 2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
30 day Readmission for Pneumonia,PInc 3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Risk-Adjusted Average Length of Inpatient Hospital Stay for Acute Myocardial Infarction (AMI),PInc 33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Risk-Adjusted Average Length of Inpatient Hospital Stay for Heart Failure (HF),PInc 34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Risk-Adjusted Average Length of Inpatient Hospital Stay for Pneumonia (PN),PInc 35,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
30 day Mortality for Acute Myocardial Infarction,PInc 4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
30 day Mortality for Heart Failure,PInc 5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
30 day Mortality for Pneumonia,PInc 6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Chronic Kidney Disease (CKD): eGFR Monitoring,PPRNET 13,Registry/QCDR,Process,Y, 59.02 - 63.42, 63.43 - 66.66, 66.67 - 72.34, 72.35 - 74.59, 74.60 - 78.25, 78.26 - 85.05, 85.06 - 86.95,>= 86.96,No,
Chronic Kidney Disease (CKD): Hemoglobin Monitoring,PPRNET 14,Registry/QCDR,Process,Y, 66.67 - 77.26, 77.27 - 83.86, 83.87 - 87.49, 87.50 - 88.63, 88.64 - 90.47, 90.48 - 91.66, 91.67 - 93.74,>= 93.75,No,
Zoster (Shingles) Vaccination,PPRNET 20,Registry/QCDR,Process,Y, 11.15 - 32.73, 32.74 - 41.89, 41.90 - 53.56, 53.57 - 56.51, 56.52 - 58.25, 58.26 - 66.42, 66.43 - 68.85,>= 68.86,No,
Appropriate Treatment for Adults with Upper Respiratory Infection,PPRNET 24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Use of Benzodiazepines in the Elderly,PPRNET 27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
NSAID or Cox 2 Inhibitor Use in Patients with Heart Failure (HF) or Chronic Kidney Disease (CKD),PPRNET 28,Registry/QCDR,Process,Y, 83.51 - 84.64, 84.65 - 85.94, 85.95 - 86.97, 86.98 - 89.25, 89.26 - 89.72, 89.73 - 90.32, 90.33 - 92.93,>= 92.94,No,
Monitoring Serum Potassium,PPRNET 29,Registry/QCDR,Process,Y, 82.03 - 82.10, 82.11 - 83.01, 83.02 - 86.19, 86.20 - 88.19, 88.20 - 90.90, 90.91 - 93.78, 93.79 - 96.60,>= 96.61,No,
Treatment of Hypokalemia,PPRNET 30,Registry/QCDR,Outcome,Y, 93.55 - 95.23, 95.24 - 96.29, 96.30 - 96.87, 96.88 - 97.32, 97.33 - 98.35, 98.36 - 99.14, 99.15 - 99.48,>= 99.49,Yes,
Angiotensin Converting Enzyme (ACE) Inhibitor or AngiotensinReceptor Blocker (ARB) Therapy(PCPI Measure #: AKID-2),RPAQIR 1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
CABG- Prolonged postoperative length of stay (PLOS),STS 1,Registry/QCDR,Outcome,Y,  8.42 -  6.59,  6.58 -  5.34,  5.33 -  4.04,  4.03 -  3.34,  3.33 -  2.48,  2.47 -  1.44,  1.43 -  0.01,  0.00,No,
CABG + Valve- Prolonged postoperative length of stay (PLOS),STS 3,Registry/QCDR,Outcome,Y, 18.75 - 13.80, 13.79 - 12.51, 12.50 - 11.12, 11.11 -  9.22,  9.21 -  6.53,  6.52 -  4.56,  4.55 -  3.71,<=  3.70,No,
Isolated Valve- Prolonged postoperative length of stay (PLOS),STS 5,Registry/QCDR,Outcome,Y,  9.84 -  8.01,  8.00 -  6.91,  6.90 -  4.89,  4.88 -  4.01,  4.00 -  3.04,  3.03 -  2.34,  2.33 -  0.01,  0.00,No,
Patient Vital Sign Assessment Prior to HBOT,USWR 13,Registry/QCDR,Process,Y, 98.74 - 99.28, 99.29 - 99.57, 99.58 - 99.70, 99.71 - 99.99,--,--,--,100.00,Yes,
"Healing or Closure of Wagner Grade 3, 4 or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT",USWR 15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Adult Kidney Disease: Blood Pressure Management,122,Registry/QCDR,Outcome,Y, 75.78 - 93.05, 93.06 - 97.83, 97.84 - 99.99,--,--,--,--,100.00,No,
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Claims,Process,Y, 40.26 - 49.99, 50.00 - 71.73, 71.74 - 93.93, 93.94 - 99.99,--,--,--,100.00,No,
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,EHR,Process,Y, 26.03 - 30.00, 30.01 - 33.32, 33.33 - 36.46, 36.47 - 39.99, 40.00 - 44.37, 44.38 - 49.99, 50.00 - 68.89,>= 68.90,No,
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Registry/QCDR,Process,Y, 41.76 - 51.26, 51.27 - 63.27, 63.28 - 78.15, 78.16 - 90.88, 90.89 - 98.77, 98.78 - 99.99,--,100.00,No,
Use of High-Risk Medications in the Elderly,238,EHR,Process,Y, 29.53 - 24.11, 24.10 - 18.67, 18.66 - 12.51, 12.50 -  5.50,  5.49 -  0.85,  0.84 -  0.01,--,  0.00,No,
Use of High-Risk Medications in the Elderly,238,Registry/QCDR,Process,Y, 21.34 - 15.80, 15.79 - 10.77, 10.76 -  6.07,  6.06 -  2.37,  2.36 -  0.71,  0.70 -  0.01,--,  0.00,No,
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,EHR,Process,Y, 27.27 - 30.76, 30.77 - 32.51, 32.52 - 33.32,--,--,--, 33.33 - 39.04,>= 39.05,No,
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment,305,EHR,Process,Y,--,--,--,--,--,--,--,>=  0.00,No,
Depression Utilization of the PHQ-9 Tool,371,EHR,Process,Y,--,--,--,--,--,  0.00 -  1.07,  1.08 - 11.53,>= 11.54,No,
Depression Utilization of the PHQ-9 Tool,371,Registry/QCDR,Process,Y,  0.32 -  0.37,  0.38 -  0.46,  0.47 -  0.55,  0.56 -  0.68,  0.69 -  0.93,  0.94 -  1.41,  1.42 - 49.99,>= 50.00,No,
Follow-up After Hospitalization for Mental Illness (FUH),391,Registry/QCDR,Process,Y, 28.00 - 55.55, 55.56 - 99.99,--,--,--,--,--,100.00,No,
Medication Reconciliation,46,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Medication Reconciliation,46,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes,
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,EHR,Process,Y, 62.50 - 77.41, 77.42 - 90.90, 90.91 - 99.99,--,--,--,--,100.00,No,
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,Registry/QCDR,Process,Y, 73.33 - 80.55, 80.56 - 86.66, 86.67 - 92.56, 92.57 - 99.99,--,--,--,100.00,No,
Anti-depressant Medication Management,9,EHR,Process,Y,--,--,--,--,  0.00 -  1.51,  1.52 - 49.99, 50.00 - 83.33,>= 83.34,No,
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis,160,EHR,Process,N,--,--,--,--,--,--,--,--,--,
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication,366,EHR,Process,N,--,--,--,--,--,--,--,--,--,
Immunizations for Adolescents,394,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Unplanned Readmission Following Spine Procedure Within the 30 Day Post?Operative Period,NPA 11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Risk -assessment for elective spine procedure,NPA 15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
Functional Outcome Assessment for Spine Intervention,NPA 3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Quality of Life Assessment for Spine Intervention,NPA 4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Patient Satisfaction with Spine Care,NPA 5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Spine?related procedure site infection,NPA 6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Complication Following Spine?Related Procedure,NPA 7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--,
Patient Centered surgical risk assessment and communication using the STS Risk Calculator,STS 7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--,
,,,,,,,,,,,,,,